Arthur Allen

Trump whacks tiny agency that works to make the America's health care safer

Sue Sheridan’s baby boy, Cal, suffered brain damage from undetected jaundice in 1995. Helen Haskell’s 15-year-old son, Lewis, died after surgery in 2000 because weekend hospital staffers didn’t realize he was in shock. The episodes turned both women into advocates for patients and spurred research that made American health care safer.

On Tuesday, the Trump administration slashed the organization that supported that research — the Agency for Healthcare Research and Quality — and fired roughly half of its remaining employees as part of a perplexing reorganization of the federal Health and Human Services Department.

Haskell, of Columbia, South Carolina, has done research and helped write AHRQ-published surveys and guidebooks on patient engagement for hospitals. The dissolution of AHRQ is dislodging scores of experienced patient-safety experts, a brain drain that will be impossible to rectify, she said.

Survey data gathered by AHRQ provides much of what is known about hospitalizations for motor accidents, measles, methamphetamine, and thousands of other medical issues.

“Nobody does these things except AHRQ,” she said. “They’re all we’ve got. And now the barn door’s closed.”

HHS Secretary Robert F. Kennedy Jr. posted on the social platform X on Tuesday that layoffs at HHS, aimed at reducing the department’s workforce by about 20,000 employees, were the result of alleged inefficacy. “What we’ve been doing isn’t working,” he said. “Despite spending $1.9 trillion in annual costs, Americans are getting sicker every year.”

But neither Kennedy nor President Donald Trump have explained why individual agencies such as AHRQ were targeted for cuts or indicated whether any of their work would continue.

At their first meeting with the leadership of AHRQ last month, officials from Trump’s Department of Government Efficiency said they didn’t know what the agency did — and that its budget would be cut by 80% to 90%, according to two people with knowledge of the meeting who were granted anonymity because of fears of retribution.

On Friday, the administration said AHRQ would merge with HHS’ Office of the Assistant Secretary for Planning and Evaluation.

An AHRQ spokesperson, Rachel Seeger, said its acting chief, Mamatha Pancholi, was unavailable to answer questions.

AHRQ focused on best use of health care dollars

Created on the foundation of an earlier agency in 1999, AHRQ has had two major functions: collecting survey data on U.S. health care expenditures, experiences, and outcomes; and funding research aimed at improving the safety and delivery of health care. It also has published tools and guidelines to enhance patient safety.

Its latest budget of $513 million amounts to about 0.04% of HHS spending.

“If you’re going to spend $5 trillion a year on health care, it would be nice to know what the best use of that money is,” said a senior AHRQ official who spoke on condition of anonymity for fear of losing his job. “To gut a 300-member, $500 million agency for no other reason than to placate a need to see blood seems really shortsighted.”

Newly sworn-in FDA Commissioner Marty Makary, a surgeon who has advocated for patient safety, wrote or co-authored at least 10 research papers supported by AHRQ funding since 1998. AHRQ research and guidelines played a key role in lowering the incidence of hospital-acquired infections — such as deadly blood infections caused by contaminated IV lines, which fell 28% from 2015 to 2023, according to the Centers for Disease Control and Prevention.

Medical residents training in the 1980s were taught that such infections were an inevitable, often fatal byproduct of heart surgery, but AHRQ-funded research “showed that fairly simple checklists about preventing infections would be effective at going to zero,” said Richard Kronick, a University of California-San Diego researcher who led AHRQ from 2013 to 2016.

Medical errors caused by missed diagnoses, drug errors, hospital infections, and other factors kill and maim tens of thousands of Americans each year. Makary published a controversial study in 2016 hypothesizing that errors killed 250,000 people a year in the United States — making medical mistakes the nation’s third-leading cause of death.

“There are all kinds of terrible things about our health care system’s outcomes and how we pay for it, the most expensive care in the world,” Kronick said. “Without AHRQ, we’d be doing even worse.”

AHRQ-funded researchers such as Hardeep Singh at Baylor College of Medicine have chipped away at patient safety risks for more than two decades. Singh devises ways to integrate technologies like telemedicine and artificial intelligence into electronic health records to alert doctors to potential prescribing errors or misdiagnoses.

Singh has 15 scholars and support staff members supported by three AHRQ grants worth about $1.5 million, he said. The elimination of the agency’s office that funds outside researchers, among the cuts announced this week, is potentially “career-ending,” he said. “We need safety research to protect our patients from harms in health care. No organization in the world does more for that than AHRQ.”

Republicans have long been skeptical of AHRQ and the agency that preceded it. Some doctors saw it as meddling in their medical practices, while some GOP Congress members viewed it as duplicating the mission of the National Institutes of Health.

But when the Trump administration proposed merging it with NIH in 2018, a House-ordered study into health research priorities validated AHRQ’s valuable role.

Now, the naysayers have triumphed.

111 AHRQ staffers fired this week

Gordon Schiff, a Harvard Medical School internist who has received AHRQ funding since 2001, was among the first to learn about policy changes there when in February he got an email from the editors of an AHRQ patient-safety website informing him “regretfully” that a 2022 case study on suicide prevention he co-authored had been removed “due to a perception that it violates the White House policy on websites ‘that inculcate or promote gender ideology.‘”

The article was not about gender issues. It briefly mentioned that LGBTQ men were at a higher risk for suicide than the general population. Schiff was offered the option of removing the LGBTQ reference but refused. He and Harvard colleague Celeste Royce have sued AHRQ, HHS, and the Office of Personnel Management over removal of the article.

“All we were doing was presenting evidence-based risk factors from the literature,” he said. “To censor them would be a violation of scientific integrity and undermine the trustworthiness of these websites.”

PSNet, the AHRQ publication where Schiff and Royce’s article appeared, has been dissolved, although its website was still up as of Wednesday. Roughly half of AHRQ’s 300 staffers resigned following the initial DOGE warning; 111 staff members were fired Tuesday, according to an email that a top executive, Jeffrey Toven, sent to employees and was shown to KFF Health News. AHRQ’s remaining leadership was in the dark about Kennedy’s plans, he said.

HHS spokespeople did not respond to requests for comment. Stephen Parente, a University of Minnesota finance professor who said he consults informally with Trump health officials, said much of AHRQ’s work could be done by others. Its most vital services have been surveys that Westat, a private research company, performs for AHRQ on contract, said Parente, who was chief economist for health policy in the first Trump administration.

At the height of the Covid pandemic, he said, data produced by AHRQ and other government sources were outclassed by private sources. To track Covid, he relied on daily feeds of private insurance data from around the country.

Still, Parente said, the virtual disappearance of AHRQ means “we’re going to lose a culture of research that is measured, thoughtful, and provides a channel for young investigators to make their marks.”

A climate of deep depression has settled over the agency’s Rockville, Maryland, headquarters, the unnamed AHRQ official said: “Almost everyone loves their job here. We’re almost all PhDs in my center — a very collegial, talented group.”

The official said he was “generally skeptical” that AHRQ’s merger with the assistant secretary’s office would keep its mission alive. The Centers for Medicare & Medicaid Services and the CDC conduct some health system quality research, but they are also losing staff, Harvard’s Schiff noted.

One of Schiff’s current AHRQ projects involved interviewing late-stage cancer patients to determine whether they could have been diagnosed earlier.

“The general public, I think, would like cancer to be diagnosed earlier, not when it’s stage 4 or stage 3,” he said. “There are things we could learn to improve our care and get more timely diagnosis of cancer.”

“Medical errors and patient safety risks aren’t going to go away on their own,” he said.

With input from Sheridan and other mothers of children who suffered from jaundice-related brain damage, AHRQ launched research that led to a change in the standard of care whereby all newborns in the United States are tested for jaundice before discharge from hospitals. Cases of jaundice-related brain damage declined from 7 per 100,000 to about 2 per 100,000 newborns from 1997 to 2012.

The misfortune of Lewis, Haskell’s son, led to a change in South Carolina law and later to a national requirement for hospitals to enable patients to demand emergency responses under certain circumstances.

Singh, a leading researcher on AI in health care, sees bitter irony in the way the Elon Musk-led DOGE has taken an ax to AHRQ, which recently put out a new request for proposals to study the technology. “Some think AI will fix health care without a human in the loop,” Singh said. “I doubt we get there by dismantling people who support or perform patient safety research. You need a human in the loop.”

This story was originally published at KFF Health News, Healthbeat’s national reporting partner.

Healthbeat is a nonprofit newsroom covering public health published by Civic News Company and KFF Health News. Sign up for their newsletters here.

The 'war on vaccines has started': Scientists blast 'ridiculous' Trump admin request

National Institutes of Health officials have urged scientists to remove all references to mRNA vaccine technology from their grant applications, two researchers said, in a move that signaled the agency might abandon a promising field of medical research.

The mRNA technology is under study at the NIH for prevention and treatment of infectious diseases, including flu and AIDS, and also cancer. It was deployed in the development of covid-19 vaccines credited with saving 3 million lives in the U.S. alone — an accomplishment President Donald Trump bragged about in his first term.

A scientist at a biomedical research center in Philadelphia wrote to a colleague, in an email reviewed by KFF Health News, that a project officer at NIH had “flagged our pending grant as having an mRNA vaccine component.”

“It’s still unclear whether mRNA vaccine grants will be canceled,” the scientist added.

NIH officials also told a senior NIH-funded vaccine scientist in New York state, who does not conduct mRNA vaccine research but described its efficacy in previous grant applications, that all references to mRNA vaccines should be scrubbed from future applications.

Scientists relayed their experiences on the condition of anonymity for fear of professional retaliation by the Trump administration.

A senior official at the National Cancer Institute confirmed that NIH acting Director Matthew Memoli sent an email across the NIH instructing that any grants, contracts, or collaborations involving mRNA vaccines be reported up the chain to Health and Human Services Secretary Robert F. Kennedy Jr.’s office and the White House.

Memoli sent a similar message ahead of the agency canceling other research, such as studies of vaccine hesitancy.

Memoli’s email on that topic bluntly stated that NIH was not interested in learning why people shun vaccines or in exploring ways to “improve vaccine interest and commitment.”

The National Cancer Institute official, who also spoke on the condition of anonymity for fear of reprisals, said that “it is reasonable to assume mRNA vaccine work is next.”

The official said a similar memo also went out regarding NIH-funded work in South Africa, which the White House has targeted over false claims that the country’s government is persecuting white people. More recently, another one went out regarding all global research collaborations, the official said.

Spokespeople for the White House, HHS, and the NIH did not respond to requests for comment.

The NIH, whose latest annual budget was $47 billion, is one of the world’s most critical sources of funding for basic biomedical research. Its mission and programs are under unprecedented scrutiny from Trump’s White House and the Department of Government Efficiency, the Elon Musk-led agency created by a Trump executive order that has directed federal agencies to prepare for widespread layoffs.

The NIH is funding at least 130 studies involving the mRNA technology in covid vaccines produced by Pfizer-BioNTech and Moderna that have been administered to billions of people worldwide.

A former government official familiar with internal discussions said that the Trump administration intends to cut some grants for mRNA vaccine research but that the timing is unclear. The person spoke on the condition of anonymity to protect relationships with the administration.

Political conservatives in the U.S. have promulgated conspiracy theories, unsupported by scientific evidence, that the shots and their relatively new technology are dangerous. This has undermined public support for covid vaccinations and mRNA research.

“There will not be any research funded by NIH on mRNA vaccines,” the scientist in New York said in an interview. “MAGA people are convinced that these vaccines have killed and maimed tens of thousands of people. It’s not true, but they believe that.”

Meanwhile, hundreds of other vaccine-related studies are in limbo. Kawsar Talaat, a vaccine researcher at the Bloomberg School of Public Health at Johns Hopkins University, has been waiting since the fall for money needed to recruit subjects for a study of an antidiarrheal vaccine.

“NIH approved our funding,” she said, “and now we’re waiting, and we don’t know if it’s going forward or going to be killed.”

The scientist in Philadelphia signaled that he believes Kennedy, a longtime anti-vaccine activist, is responsible for the NIH’s turn against mRNA research.

“Kennedy’s war on vaccines has started,” the scientist told his colleague.

The scientist in New York said that it was “ridiculous” to remove mRNA language from the grant applications. But “if my grant is rejected for any reason,” the scientist said, “people in my lab will lose their jobs.”

“I’ve worked with some of them for 20 years,” the scientist added. “They have children and families. There is a real climate of fear in academia about this now, especially among vaccine scientists.”

“My grant does not involve a request for funds to conduct mRNA vaccine experiments,” the scientist said, “so my principal concern was to avoid word-search flags that, at minimum, would lead to delays in any funding.”

While tenured research professors at universities generally receive a salary from their institution, the staffers who work in their labs and offices are often paid through NIH grants. The 2023 Nobel Prize in physiology or medicine was given to two scientists for developing mRNA vaccines, through work that relied on pharmaceutical companies and on NIH scientists working under infectious disease specialist Anthony Fauci.

According to Sen. Bill Cassidy, a Louisiana Republican who chairs the chamber’s Health, Education, Labor and Pensions Committee, Kennedy promised during his Senate confirmation process that he would protect “the public health benefit of vaccination” and “work within the current vaccine approval and safety monitoring systems, and not establish parallel systems.”

Cassidy, a physician, had expressed reservations about confirming Kennedy to the HHS post and challenged his anti-vaccine views during a confirmation hearing. He ended up voting for him, he said, because Kennedy had agreed to work closely with Cassidy and his committee.

However, Kennedy has faced scrutiny in his first weeks in office for his handling of a large measles outbreak among mostly unvaccinated people in Texas that has led to the death of a child, the first U.S. measles death in more than a decade. A patient who tested positive for measles died in New Mexico, but the cause hasn’t been confirmed. Instead of urging vaccination against the disease, an almost surefire way to prevent infection, Kennedy has blamed malnourishment for the outbreak, promoted unproven treatments for measles, and falsely claimed in one Fox News interview that the vaccine is ineffective and even dangerous.

Cassidy did not respond to a request for comment on the NIH’s potential abandonment of mRNA vaccine research.

As part of the Trump administration’s push to examine spending on mRNA vaccines, health officials are reviewing a $590 million contract for bird flu shots that the Biden administration awarded to Moderna, Bloomberg News has reported. Legislation introduced by GOP lawmakers in at least seven states is aimed at banning or limiting mRNA vaccines. In some cases, the measures would hit doctors who give the injections with criminal penalties, fines, and the possible revocation of their licenses.

Stephanie Armour and Céline Gounder contributed to this article.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF—an independent source of health policy research, polling, and journalism. Learn more about KFF.

Subscribe to KFF Health News' free Morning Briefing.

This article first appeared on KFF Health News and is republished here under a Creative Commons license.

The Price of Plump Penises

If an implant of skin from a corpse could give you lips like Kim Basinger or a schlong like Dirk Diggler's, would you opt for the operation? Would it matter to you that some poor kid in a burn unit was dying for lack of the skin that you bought to improve your pout, or your boudoir clout?

If so, then you are probably not one of the 500,000 people who got collagen injections last year to puff up their lips, cheeks and other body parts. Most of the collagen came from cows, but perhaps 20 percent came from dead people. Yes, that's right: Flesh derived from the skin of the dead is being injected and sewn into the bodies of the living -- at times for reconstructive purposes, at times for aesthetic ones.

"When we tell the patients where it comes from, a fair number say, 'I don't think I can do that.' But the others accept it," says Ron Perlman, a Washington plastic surgeon who has done about 140 lip enlargements using Alloderm, a product made from processed skin. He says he knows of beauty queens and magazine models with lips aquiver in Alloderm.

This may appear repulsive and almost cannibalistic, but the donors, at least, aren't complaining. What may be most worrisome about the practice, which was laid out in a five-part Orange County (Calif.) Register report last month, is that demand for the skins of the dead for cosmetic purposes may be taking away skin from burn victims.

The Register series depicted the world of tissue donation as peopled by greedy entrepreneurs sidestepping federal laws that prohibit profiteering from body parts. It pointed out that while tight federal protocols require that transplantable livers, kidneys, lungs and other organs go to the people who need them most, this is not the case with the rest of the body.

Once certain viable organs have been removed, it's open season on the corpse, providing its donor hasn't set specific limits. And some of the scavenging is for-profit. Commercial companies and nonprofit tissue banks have set up chop shops at hospitals and morgues that strip down cadavers for parts.

Lurid as this sounds, most of the material is put to good use, whether or not someone makes a profit along the way. Bones are ground up for reconstructive surgery and dental implants, eyes removed for corneal transplants and skin is flayed for burn patients as well as to rebuild damaged flesh.

But the Register reported that some burn centers are short on skin because they can't compete with companies such as LifeCell, in Texas, and Collagenesis, in Massachusetts, which convert the skin into a product that can be transplanted without allergic rejection.

"It used to be that skin and tissue banks were little mom and pop organizations associated with burn centers," says Dr. Glenn Warden, chief surgeon at Shriners Burn Center, which treats about 1,000 severe burn victims each year in Cincinnati. "Now, some of the tissue banks send their skin to the manufacturers because they can get more money for it. That's a problem."

Neither Warden nor the American Burn Association could point to specific cases in which a burn patient died because skin had been sold to a commercial company instead of a burn center. But Warden says he wouldn't be surprised at such a case, given the disparity in prices paid by commercial skin companies and burn centers.

Shriners and a handful of other big burn centers have affiliated tissue banks devoted to serving their patients. But officials at the Cincinnati tissue bank have told Warden they could get three times as much money from the collagen companies as they get from the hospital, he says.

"There's always been a shortage of skin for grafts. The poor burn patients in general do not have much money," he says. "They are not the wealthy people. They may not have insurance. They may not have anything."

LifeCell and Collagenesis officials deny they are robbing the sick to puff up the vain. Eighty percent of Alloderm, LifeCell's product, goes to treat burn victims, according to Glenn Greenleaf, a company official. While the remaining 20 percent is shipped to plastic surgery offices, not all their operations are frivolous.

To be sure, cosmetic surgery offices are swelled to bursting with patients seeking tummy tucks (up 75 percent since 1997), boob jobs (up 89 percent) and Botox injections (up 665 percent). Nearly 325,000 women had their breasts surgically adjusted in America last year, according to the Society for Aesthetic Plastic Surgery.

But "the cosmetic portion is a small portion of the overall market" for skin, says Judith Bednarz of Collagenesis, which makes Dermologen. And to the extent that poor body image fuels her company's business, she adds, "It helps support research and development for more critical needs."

Arthur Allen writes on health, science and other issues for Salon. He lives in Washington.

BRAND NEW STORIES
@2025 - AlterNet Media Inc. All Rights Reserved. - "Poynter" fonts provided by fontsempire.com.